LifeAgain

LifeAgain is a South Korean precision medicine and data-driven healthcare company specializing in cancer survivorship and chronic disease management. Founded in 2018, the company utilizes clinical big data and artificial intelligence to provide personalized health interventions, including symptom monitoring, nutrition, and exercise guidance for oncology patients. LifeAgain is a key participant in South Korea's national 'K-Cancer Platform' initiative, collaborating with top-tier medical institutions like Seoul National University Hospital to advance precision diagnosis and secondary cancer prevention. The company's business model leverages Electronic Medical Records (EMR) and Patient-Generated Health Data (PGHD) to develop validated digital therapeutics (DTx) for major cancers. By integrating clinical evidence with real-time lifestyle data, LifeAgain aims to enhance post-treatment outcomes and long-term survival. The firm is backed by prominent Korean venture capital firms and is positioning itself as a leader in the Asian digital oncology market.